Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03814356 · ClinicalTrials.gov registry record · Phase 1
Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness
A Phase 1 study of Coma and Anoxic Brain Injury, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03814356 is a Phase 1 study of Coma and Anoxic Brain Injury that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 10 participants, below the 85-participant average among 3 other Coma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03814356, a Phase 1 study of Coma and Anoxic Brain Injury, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 1 of the STIMPACT trial is an open label,dose-escalation,safety study of intravenous (IV) methylphenidate (MPH) therapy in patients with disorders of consciousness (DoC) caused by severe brain injuries.
Conditions Studied
Interventions
- DRUG Methylphenidate
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-08-24 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03814356
The ClinicalTrials.gov registry entry for NCT03814356 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 85-participant average among 3 other Coma trials with a reported enrollment target (88% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Coma appearing as the primary indexed condition, and to 1 intervention - of which Methylphenidate is the first listed.
NCT03814356 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03814356 about?
NCT03814356 is a clinical study titled "Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness". Phase 1 of the STIMPACT trial is an open label,dose-escalation,safety study of intravenous (IV) methylphenidate (MPH) therapy in patients with disorders of consciousness (DoC) caused by severe brain injuries.
What is the current status of trial NCT03814356?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-08-24. Estimated completion is 2026-06-30.
What conditions does trial NCT03814356 study?
This clinical trial studies the following conditions: Coma, Anoxic Brain Injury, Consciousness, Level Altered, Brain Injury Traumatic Severe (Diagnosis).
What interventions are being tested in trial NCT03814356?
The interventions under investigation include: Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT03814356?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03814356 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.